Treatment of lung metastasis from renal cell carcinoma with lymphokine-activated killer cells and interleukin-2.

用淋巴因子激活的杀伤细胞和白介素-2 治疗肾细胞癌肺转移。

• 批准号: 62480336
• 负责人: UENO Akira
• 金额: $ 3.84万
• 依托单位: Yamanashi Medical College
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for General Scientific Research (B)
• 财政年份: 1987
• 资助国家: 日本
• 起止时间: 1987 至 1988
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-62480336/
• 关键词: renal cell carcinoma; lung metastasis; adoptive immunotherapy; lymphokine-activated killer cell; lymphokine-activated killer cell; 腎癌; LAK細胞; インターロイキン2

The conditions to induce lymphokine-activated killer (LAK) cells were investigated at first. Concentrations of serum in culture media, 1, 2 and 5% had no effect on induced LAK activity. The best density of peripheral blood lymphocytes in culture bottle was 2x10^6/ml, and the most effective concentration of recombinant interleukin-2 (<@2r<@D2IL-2) to generate LAK cells was 3u/ml. Cytotoxicity against Daudi cell appeared on the second day of culture and reached a peak on the third day. There was no difference in induced LAK activity between standing and rolling culture.One patient with lung metastasis from renal cell carcinoma was treated with LAK cells and <@2r<@D2IL-2. LAK cells and <@D2r@>D2IL-2 were administered 11 times during 14 months, the first 2 times intravenously and 9 times via bronchial artery. The total number of LAK cells injected was 16.1x10<@D19@>D1 cells. Induced LAK activities gradually decreased and reached minimum at 6th treatment. From the 6th treatment plasma exchange was performed the day before administration of LAK cells. Induced LAK activities recovered from the 7th treatment. Despite these treatments the size of the metastatic lesion gradually increased.

本文首先对LAK细胞的诱导条件进行了研究。培养液中血清浓度为1%、2%和5%对诱导的LAK活性无影响。培养瓶中外周血淋巴细胞的最佳浓度为2 × 10 ~ 6/ml，重组白细胞介素-2（<@2r<@D_2IL-2）产生LAK细胞的最佳浓度为3u/ml。对Daudi细胞的细胞毒作用在培养的第2天出现，第3天达到高峰。1例肾癌肺转移患者用LAK细胞加<@2r<@D2IL-2治疗。LAK细胞和<@D2r@> D2 IL-2在14个月内共给药11次，前2次静脉注射，9次经支气管动脉注射。注射的LAK细胞总数为16.1 × 10 <@D19@>D1细胞。诱导的LAK活性逐渐下降，至第6次处理时达到最低。从第6次治疗开始，在给予LAK细胞的前一天进行血浆置换。诱导的LAK活性从第7次治疗开始恢复。尽管这些治疗，转移病灶的大小逐渐增加。

项目成果

田坂捷雄: クリニカルファーマシー. 15. 41-44 (1988)

田坂芳雄：临床药学。15. 41-44 (1988)

Hideaki Iizuka: "Sudy or lymphokine-activated killer (LAK) cells. I Improved LAK cell induction in vitro" Yamanashi Medical Journal. 3. 97-103 (1988)

Hideaki Iizuka：“Sudy 或淋巴因子激活的杀伤 (LAK) 细胞。我改进了 LAK 细胞的体外诱导”山梨医学杂志。

Noboru Yabusaki: "Adoptive immunotherapy for lung metastasis from renal cell carcinoma." Yamanashi Medical Journal.

Noboru Yabusaki：“肾细胞癌肺转移的过继免疫疗法。”

田坂捷雄: クリニカル ファーマシー. 15. 41-44 (1988)

田坂芳雄：临床药学。15. 41-44 (1988)

Kachio Tasaka: "Tumor immunotherapy with LAK cells." Clinical Pharmacy. 4. 41-44 (1988)

Kachio Tasaka：“LAK 细胞的肿瘤免疫疗法。”